For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr…
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Learn more about and submit your abstract to the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma.…
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
An abstract is unavailable.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Yang et al. report that the intracellular CD28 in triple negative breast cancer (TNBC) cells promotes PD-L1-mediated immune escape. Inhibition of CD28 in cancer cells decreases…
